Skip to main content

Table 1 General characteristics of 546 patients with PTMC

From: A novel tool for predicting the risk of central lymph node metastasis in patients with papillary thyroid microcarcinoma: a retrospective cohort study

Item

Overall

CLNM(%)

P.Value

negative (n = 383)

positive(n = 163)

Age (years)

   

< 0.001***

  < 45

205 (37.5%)

125 (32.6%)

80 (49.1%)

 

 45 ≤ age<55

194 (35.5%)

140 (36.6%)

54 (33.1%)

 

  ≥ 55

147 (26.9%)

118 (30.8%)

29 (17.8%)

 

Sex:

   

0.522

 Female

420 (76.9%)

298 (77.8%)

122 (74.8%)

 

 Male

126 (23.1%)

85 (22.2%)

41 (25.2%)

 

TSH

2.10 [1.28;3.12]

2.15 [1.31;3.12]

2.07 [1.23;3.11]

0.538

Tumor_size

   

< 0.001***

  < 0.65

324 (59.3%)

260 (67.9%)

64 (39.3%)

 

  ≥ 0.65

222 (40.7%)

123 (32.1%)

99 (60.7%)

 

Aspect_ratio

   

0.380

  < 1

264 (48.4%)

180 (47.0%)

84 (51.5%)

 

  ≥ 1

282 (51.6%)

203 (53.0%)

79 (48.5%)

 

Capsular invasion

   

< 0.001***

 No

487 (89.2%)

354 (92.4%)

133 (81.6%)

 

 Yes

59 (10.8%)

29 (7.57%)

30 (18.4%)

 

Calcification

   

0.006**

 No

200 (36.6%)

155 (40.5%)

45 (27.6%)

 

 Yes

346 (63.4%)

228 (59.5%)

118 (72.4%)

 

Multifocality

   

< 0.001***

 Multiple

192 (35.2%)

106 (27.7%)

86 (52.8%)

 

 Solitary

354 (64.8%)

277 (72.3%)

77 (47.2%)

 

Hashimotos thyroiditis

   

0.020*

 No

445 (81.5%)

302 (78.9%)

143 (87.7%)

 

 Yes

101 (18.5%)

81 (21.1%)

20 (12.3%)

 

Nodular goiter

   

0.757

 No

322 (59.0%)

228 (59.5%)

94 (57.7%)

 

 Yes

224 (41.0%)

155 (40.5%)

69 (42.3%)

 
  1. TSH thyroid stimulating hormone, HT Hashimoto’s thyroiditis, CLNM central lymph node metastasis; *P < 0.05; **P < 0.01; ***P < 0.001